

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**SCHEDULE 14A**  
**Proxy Statement Pursuant to Section 14(a) of the**  
**Securities Exchange Act of 1934**  
**(Amendment No.    )**

---

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

- ☐ Preliminary Proxy Statement
- ☐ **Confidential, for Use of the Commission Only** (as permitted by Rule 14a-6(e)(2))
- ☐ Definitive Proxy Statement
- ☒ Definitive Additional Materials
- ☐ Soliciting Material under §240.14a-12

**Amarin Corporation plc**  
(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

- ☒ No fee required.
- ☐ Fee paid previously with preliminary materials.
- ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
-

*Below is a slide deck prepared by Amarin Corporation plc (the “Company”) to facilitate discussions beginning on February 6, 2023. The Company has filed a definitive proxy statement (DEF14A) and WHITE proxy card with the U.S. Securities and Exchange Commission in connection with its solicitation of proxies from shareholders at the Company’s 2023 Special General Meeting of Shareholders. Shareholders are strongly encouraged to read such proxy statement and accompanying WHITE proxy card as they contain important information. The Company also has established a website, <https://www.voteamarin.com/>, to communicate with the Company’s shareholders regarding its solicitation of proxies from shareholders at the Special General Meeting.*

# **NEW Amarin: Charting a Path to Value Creation as a Global, Diversified Cardiometabolic Player**

February 2023

The Amarin logo, featuring a stylized 'A' icon followed by the word 'AMARIN' in a serif font, with a registered trademark symbol (®) to the upper right.

## Forward Looking Statements & Disclaimer

This presentation contains forward-looking statements which are made pursuant to U.S. federal securities law, including beliefs about Amarin's key achievements in 2022 and the potential impact and outlook for achievements in 2023 and beyond; Amarin's 2023 financial outlook and cash position; strategies to ensure profit maximization; Amarin's strategic direction and actions management has taken to stabilize our U.S. business and position Amarin for growth and value creation; the runway for growth as Amarin's strategic focus shifts toward expanding the business in Europe and other international markets; potential for positive pricing and successful reimbursement decisions in Europe; objectives of Amarin's cost reduction program and other cash preservation initiatives, and diversification; Amarin's commitment to identifying and rigorously evaluating new highly qualified, independent candidates for Amarin's Board of Directors, including full, comprehensive evaluation of Sarissa Capital Management LP's proposed nominees; and the overall potential and future success of VASCEPA (marketed as VAZKEPA in Europe) and Amarin generally.

These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including Amarin's annual report on Form 10-K for the full year ended 2021, and Amarin's quarterly reports on Form 10-Q for the quarters ended March 31, 2022, June 30, 2022, and September 30, 2022, and its other filings. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Amarin undertakes no obligation to update or revise the information contained in its forward-looking statements, whether as a result of new information, future events or circumstances or otherwise. Amarin's forward-looking statements do not reflect the potential impact of significant transactions the company may enter into, such as mergers, acquisitions, dispositions, joint ventures or any material agreements that Amarin may enter into, amend or terminate.

**THIS PRESENTATION IS INTENDED FOR COMMUNICATION  
WITH INVESTORS AND NOT FOR DRUG PROMOTION.**

---

AMARIN, VASCEPA, VAZKEPA and REDUCE-IT are trademarks of Amarin Pharmaceuticals Ireland Limited. VAZKEPA is a registered trademark in Europe and other countries and regions and is pending registration in the United States.

---



# Change was Needed – and is Now Well Underway

- **Transformation to New Amarin is Underway**

- Actively overcoming past challenges with transformation plan; proactively pivoted to focus on global commercialization strategy
- Implemented fundamental changes to U.S. cost structure; delivered actual savings of \$50M in the second half of 2022 and on track to achieve \$100M by mid-2023
- 70% new executive leadership team; collectively launched 25+ cardiovascular and related products in 45+ markets

- **Winning Commercial Strategy to Drive Short- And Long-Term Value Creation**

- \$1 billion-plus peak opportunity in Europe and another potential \$1 billion opportunity internationally
- Achieved attractive reimbursement and pricing in five European countries and advanced five additional European markets to pricing negotiation in 2022
- Achieved six international regulatory approvals in 2022 and one in January 2023
- U.S. business maintained ~60% market share with four generic entrants – exceptional for any drug facing two years of generic competition
- Generated four consecutive quarters of U.S. revenue stabilization

- **New Board Members are Agents of Change**

- Undertaken comprehensive, independent and transparent Board refreshment process since October 2021 with assistance of global, leading independent search firm
- Six new independent directors appointed in 2022; appointed new Board leadership
- New directors bring wealth of highly relevant experience in international, in particular European, cardiovascular and related product launches
- Per Wold-Olsen, Chairman, brings key expertise and leadership needed to guide Amarin's next phase
- Remains open to strategic dialogue; the Board would evaluate any bona fide offer if they receive one

- **Sarissa's Campaign is Misguided and Risks Value Destruction**

- Sarissa has proven it does not understand Amarin's business, has no plans and no ideas
- Risks losing substantial momentum and jeopardizes value creation opportunity
- Sarissa's slate of nominees is underqualified to guide the Company at this critical juncture in our transformation

# 01

## **Transformation is Underway**

---

Amarin is Overcoming Past Challenges With a Best-in-Class Leadership Team and Strategy to Drive Short- and Long-Term Value

## Transformed And Strengthened Core Leadership Team

  
**25+**  
CV & RELATED  
PRODUCTS LAUNCHED

  
**100+**  
YEARS  
IN CV

  
**45+**  
DIFFERENT  
MARKETS



**Laurent Abuaf**  
SVP, President  
of Europe  
August 2021



**Dr. Nabil Abadir**  
SVP, Chief  
Medical Officer  
April 2022



**Tom Reilly**  
SVP, Chief  
Financial Officer  
June 2022



**Lisa DeFrancesco**  
SVP, Corporate  
Affairs and  
Investor Relations  
January 2022



**David Keenan**  
SVP, Technical  
Operations  
May 2022



**Jordan Zwick**  
SVP, Corporate  
Business  
Development  
May 2022



**Aaron Berg**  
EVP, President-U.S.  
November 2012



**Steven Ketchum, PhD**  
EVP, Chief Scientific  
Officer  
February 2012



**Donna Pasek**  
SVP, Human  
Resources  
May 2012



**Caroline Maraval**  
VP, Chief of Staff  
March 2022

AstraZeneca 

 **MERCK**

 **NOVARTIS**

 **Bristol Myers Squibb™**

**GSK**

**KOS**  
Pioneering Medicines  
for a Better Life®

 **Reliant®**  
PHARMACEUTICALS

 **Allergan**



FEBRUARY 23

5

## Established Best-in-Class European Commercialization Team

  
**30+**  
CV & RELATED  
PRODUCTS LAUNCHED

  
**125+**  
YEARS  
IN CV

  
**40+**  
DIFFERENT  
MARKETS



**Laurent Abuaf**  
SVP, President  
of Europe



**Scott Curley**  
UK – General  
Manager




**Luca Ruffini**  
Italy – General  
Manager



**Henrik  
Asmussen**  
Mid Europe &  
Nordics –  
General Manager



**Salvador Lopez**  
Iberia – General  
Manager



**Hakima  
Hannachi**  
Head of Medical  
Affairs Europe



**Laurent Josse, PhD**  
France – General  
Manager



**Tamara Barghout**  
Head of  
Marketing &  
Launch Lead



**David Jakouloff, MD**  
Head of Market  
Access



**Christos  
Papadopoulos**  
CEE – General  
Manager

AstraZeneca



NOVARTIS

Pfizer

AMGEN

janssen



Bristol Myers Squibb™

GSK

abbvie



MSD



MENARINI

Biogen





FEBRUARY 23

6

## Amarin's New Management Team Took Rapid Action In Response to Generic Entry

### Exceptional Outcomes Led to Significant Investment by Prior Management

### Legal Setback

- **2011**  
Start of the landmark cardiovascular outcomes **REDUCE-IT®** trial  

- **2018**  
Publication of REDUCE-IT® study results in New England Journal of Medicine (Nov '18)  

- **2019**  
• FDA approval for Cardiovascular Risk Reduction ("CVRR")  
• EMA submission accepted
- **2020**  
Launch of **VASCEPA®** for CVRR in the United States
- **April 2021**  
Amarin loses patent protection in the United States

### Investments to Support U.S. Commercialization

- **Dramatic expansion of U.S. salesforce** within a single quarter by 400+
- **Amarin made substantial purchase commitments with suppliers**
  - In anticipation of a massive launch, **prior Amarin management contracted with multiple suppliers to ensure redundancy**
  - **18-month lead-time was required** to start production
  - **Contracts were long-dated** and **required high purchase commitments**
- **Expanded global footprint**



FEBRUARY 23

<sup>1</sup> Includes \$18M of settlements

## New Management Immediately Took Action

### Comprehensive Response to Generic Entry

- ✓ **Negotiated exclusivity to stabilize revenues post-generic entry**
- ✓ **Implemented salesforce reduction from ~825 to ~85**
  - ✓ **Phased reduction to evolving generic market backdrop – 50% in Oct'21 followed by 75% in Jun'22**
- ✓ **Additional corporate layoffs of ~10% in Jun'22**
- ✓ **Substantial progress on supply chain renegotiations, reducing supply purchases by \$150M between 1H'22 and 2H'22**
- ✓ **Successful renegotiation of Corporate HQ lease**

**Delivered Actual Savings of \$50M in 2H 2022 and On Track to Achieve \$100M by Mid-2023**



# Simultaneously, We Have Pivoted to Focus on the Global Opportunity

Amarin is Successfully Executing a Global Commercialization

- **August 2021**  
Karim Mikhail  
appointed as new CEO

- **September 2021**  
Commercial hub in  
Zug, Switzerland  
became operational

- **2022**
  - National reimbursement received in UK, Sweden & Finland
  - Individual reimbursement received in Austria and Denmark



★ **Current position**

- **2024**
  - International approvals anticipated

## PIVOT TO EU COMMERCIALIZATION & GLOBALIZATION

- **2021**
  - Initiated European launch activities
  - March '21: EC approves icosapent ethyl (branded VAZKEPA®)

**Vazkepa**  
(icosapent ethyl)

- April '21: MHRA approves icosapent ethyl in Great Britain



- **2023**
  - Launch across new markets and expand digital strategy

**Vazkepa**  
(icosapent ethyl)

- Reimbursement decisions and approvals expected in key countries



- In process of seeking scientific advice from EMA on FDC program

- **BEYOND**  
**Multi-billion dollar**  
**ex-US opportunity**



FEBRUARY 23

## Amarin Leadership Took the Right Actions in 2022

Focus on Operational Excellence to Enhance Value

### SUCCESSFUL EXECUTION ON GLOBAL COMMERCIALIZATION

- Attractive reimbursement and pricing in 5 European countries
- Advanced 5 additional European markets to pricing negotiation
- Achieved 6 international regulatory approvals
- Hired ~200 European team members with significant CV-MET launch experience and established Zug HQ

### SIGNIFICANT PROGRESS ON CASH PRESERVATION INITIATIVES

- Delivered actual savings of \$50M in the second half of 2022 and on track to achieve \$100M by mid-2023
- Renegotiations of supply agreements continue to progress resulting in reduction of inventory purchases

### TRANSFORMED LEADERSHIP TEAM AND BOARD

- Added global, pharma, leadership and financial expertise
- Built a leading European leadership team to best execute on significant commercial opportunity
- 70% of executive leadership team new in 2022



FEBRUARY 23

10



# Continued Solid Execution Against Ambitious Objectives

We Made Progress Against All Three Strategic Pillars

## Portfolio Diversification

Furthered value of IPE through data evidence  
Progressing FDC pipeline

## Operational Evolution

Reacted swiftly in the US to save costs, while stabilizing revenue  
Focused on operational excellence

## Geographic Expansion

Achieved reimbursement decisions and launched in 5 markets:  
Sweden, UK, Austria, Denmark and Finland  
Six International Regulatory Approvals Achieved



## The Next Chapter – Becoming A Diversified Cardiometabolic Player



## The Next Chapter – Becoming A Diversified Cardiometabolic Player

### Rationale for Development of an FDC Portfolio

#### Life Cycle Management Of VAZKEPA®

An FDC launch can potentially bring significant **value to the VASCEPA® /VAZKEPA®** franchise globally

#### Greater Patient Convenience And Adherence

Reduced pill burden, meaning **greater convenience** which translates into **increased adherence** with a positive impact on patient outcome as well as commercially

#### Enhance The Value Proposition

If successful, the FDC product would carry the **most significant CV risk outcome benefit label** and potentially additional protection for patients

Process underway to seek Scientific Advice from EMA



# 02

## **Amarin has a Winning Commercial Strategy**


---

Foundation in Place for Geographic Expansion with Early  
Success Accelerating

## We Have Made Significant Progress in Europe



Entering 2022 we had  
**one market** in price  
negotiations



# Multiple Markets Are Transitioning to Launch





At year end we had  
**VAZKEPA®** available in  
**5 markets**, and in the  
pricing negotiation stage in  
another **5 markets**

	1. Regulatory Approval	2. Submission of Market Access & Reimbursement Dossiers	3. Scientific Evidence Assessm. / Recommendation	4. Reimbursement Price Negotiations	5. Country Launch Pricing announcement & Publication
Austria		Individual reimbursement > national reimbursement expansion 2023			<b>Launched</b> (Individual Reimbursement)
Denmark		Individual reimbursement > national reimbursement expansion 2023			<b>Launched</b> (Individual Reimbursement)
England/Wales		National reimbursement			<b>Launched</b>
Finland		National reimbursement			<b>Launched</b>
France		CEPS negotiations ongoing			2023/2024 (expected)
Germany		Amarin suspended VAZKEPA® supply and German business operations			Final Arbitration Decision November 2022
Italy		Positive CTS, CPR negotiations started			2023 (expected)
Netherlands		Positive ZIN recommendation, MoH pricing negotiations ongoing			2023 (expected)
Norway		Pending NOMA decision			2023 (expected)
Portugal		INFARMED submission ongoing			2023 (expected)
Scotland		SHC submission ongoing			2023 (expected)
Spain		Positive IPT recommendation, Pending MoH decision			2023 (expected)
Sweden		National reimbursement			<b>Launched</b>
Switzerland		BAG submission ongoing			2023 (expected)
Israel					2023 (expected)



# The Path to \$1BN+ Market Opportunity for Amarin is Within Reach



✓ **Launched market**  
**Population in M**

**PRICING**  
~\$175/mo<sup>1</sup>

**UK & IRELAND** ✓

~4.8

Estimated eCVD prevalence

~1.1

Estimated eCVD eligible patients for Vazkepa EMA label

**NORDICS** ✓

~1.8

Estimated eCVD prevalence

~0.3

Estimated eCVD eligible patients for Vazkepa EMA label

**PRICING**

~\$160/mo<sup>2</sup>

**PRICING**

~\$223/mo<sup>2</sup>

**PRICING**

~\$169/mo<sup>2</sup>

**FRANCE**

~6.0

Estimated eCVD prevalence

~1.3

Estimated eCVD eligible patients for Vazkepa EMA label

**ITALY**

~4.5

Estimated eCVD prevalence

~0.7

Estimated eCVD eligible patients for Vazkepa EMA label

**IBERIA**

~3.7

Estimated eCVD prevalence

~0.8

Estimated eCVD eligible patients for Vazkepa EMA label

**CEE**

~12.9

Estimated eCVD prevalence

~1.6

Estimated eCVD eligible patients for Vazkepa EMA label

**MID EU** ✓

~3.1

Estimated eCVD prevalence

~0.8

Estimated eCVD eligible patients for Vazkepa EMA label

**PRICING**

~\$218/mo<sup>2</sup>



Mid-EU: Netherlands, Austria, Belgium, Switzerland; CEE: Greece, Poland, Czech Republic, Slovakia, Hungary, Estonia, Latvia, Lithuania, Croatia, Slovenia, Serbia, Montenegro, Bosnia, N. Macedonia, Bulgaria, Romania, Cyprus and Malta; Nordics: Sweden, Finland, Norway, Denmark  
 FEBRUARY 23 \*CEE: due to lack of availability of local data (with the exception of some countries like Greece) we have assumed only 50% of eCVD patients on statins (vs 70% and more in west Europe) and 23% of patients with elevated TG which is the low end of the rest of Western Europe  
 PLEASE note that CEE DOES NOT include RUSSIA, ISRAEL, UKRAINE and the CIS countries; population figures rounded to the nearest 50  
<sup>1</sup>U.K. pricing based on announced guidance of £144/month and exchange ratio of \$1.24/£; <sup>2</sup>Swedish pricing based on announced guidance of 1,640kr/month and exchange ratio of 0.098 \$/kr; Danish pricing based on announced guidance of 1,488DKK/month and exchange ratio of 0.1600 \$/DKK; Finland and Austria pricing based on announced guidance of €200/month and €195/month respectively and exchange ratio of \$1.09/€

## U.K. Pricing & Reimbursement and Launch Highlights



### April 8, 2021

**MHRA Approves VAZKEPA** for reducing the risk of cardiovascular events in statin treated eCVD with fasting TG > 1.7 mmol/l, LDL-C 1.04 - 2.60 mmol/l (>70 KOL endorsements)

### June 2022

Amarin UK Officially Operational  
Key Account Managers in the field

### July 2021

Amarin Completes VAZKEPA NICE Submission

### July 2022

Amarin Receives Final NICE Guidance for VAZKEPA Reimbursement for statin treated eCVD with fasting TG > 1.7 mmol/l, LDL-C 1.04 - 2.60 mmol/l

### November 2022

NICE publishes new National Lipid Guidelines including TG testing & Vazkepa


### May 2021 – July 2022

Amarin builds UK Commercial team





# Successful Price Negotiation Compared to Other Oral Analogues



# Strong Initial Market Access Performance in the U.K.




## Uptake from NICE TA Slide

Cumulative positive formulary inclusion from NICE TA

Formulary Types: All/All

Countries: All



- 83/142 formularies, > DS Nilemdo & Novartis' Leqvio
- 19/20 unlocked priority accounts = access to 50% eligible patient population
- 65% (13) have AI 100% (any HCP can Rx), 25% (5) have AI 65% (Specialists can Rx)

Priority Account	Eligible Patient Population	Availability Index
Cheshire & Merseyside ICB (Pan Mersey)	29,000	100
North East & North Cumbria ICB (County Durham)	28,597	100
Greater Manchester ICB (GMMMG)	27,366	100
North West London ICB (Chelsea and Westminster)	20,100	100
North East London ICB (Barts)	19,420	100
Northern Ireland	18,072	100
Kent and Medway ICB (East Kent, West Kent)	17,802	100
Hampshire & the Isle of Wight ICB	17,398	100
South East London ICB	17,263	65
Sussex ICB (East Sussex West Sussex)	16,320	100
West Yorkshire ICB (Leeds)	15,236	100
Birmingham & Solihull ICB	11,192	5*
Nottingham & Nottinghamshire ICB	9,980	65
Derby & Derbyshire ICB	9,845	30
Bedfordshire, Luton & Milton Keynes ICB	9,142	100
Bath, North East Somerset, Swindon & Wiltshire ICB	8,907	65
Herefordshire & Worcestershire ICB	7,554	65
Dorset ICB	7,436	100
Lincolnshire ICB	7,284	65
Buckinghamshire Oxfordshire & Berkshire ICB	6,469	100
<b>Unlocked to date</b>	<b>293,191</b>	
Eligible Patient Population / Total	304,383 / 586,000	



FEBRUARY 23

20

# COVID Turned Germany From an Easy, Open Access Marketplace to a Challenging Marketplace



## March 2022 – The German Government Announced Exceptional Healthcare Austerity measures

- Germany has a “discretionary” pricing period where companies are able to set their own price prior to negotiating with the government
  - Reduced from 12 months to 6 months as a result of austerity measures
- Mandatory rebate increase from 7 to 19% in 2023
- Extension of pricing moratorium by 4 years
  - Only inflation catch up permitted
- Additional rebate for combination products of 15%
- Improvement of negotiation position for the sick funds



## International Expansion A Significant Focus – 20 Markets By 2024



**NEXT WAVE EXPECTED TO BE UP TO  
13 BY YEAR END 2024**

Additional markets pending,  
including China

New markets **represent 50M+ patients**

**Negotiate Partnership Opportunities  
to Drive Access While Maintaining  
Flexibility**

**Supported by REDUCE-IT® Study  
and U.S. FDA and EMA Filings**



FEBRUARY 23 Note: The company is pursuing expansion into these various additional markets and the status of regulatory and/or patient approval will vary market to market.  
Patient populations indicate prevalence of cardiovascular disease per Journal of the American College of Cardiology, Vol. 80 published 11/25/22

# Proven Ability to Negotiate Attractive International Partnerships



## CANADA

- ✓ Out-licensed Canada rights in 2017
- ✓ Favorable pricing & reimbursement outcome
- ✓ HLS partnered with Pfizer's Primary Care organization to drive commercialization
- ✓ Peak sales estimate of C\$250-300M

## MENA

- ✓ Distribution agreement since 2016
- ✓ Approval achieved across multiple geographies

## CHINA/HONG KONG

- ✓ Full development & commercialization agreement since 2015
- ✓ Mainland China final regulatory decision delayed due to COVID
- ✓ Edding Pharm's current timeline supports a Q1 approval

## Targeting Additional Distribution Agreements for RoW Geographies




FEBRUARY 23 <sup>1</sup> Monthly treatment cost based on a 2-gram twice daily administration, assumes -CA0529A/mo with 0.75 C\$CAD/USD exchange ratio

23

# Managing The Dynamic U.S. Situation

Two Years Into Generic Competition

Total IPE Norm TRx Trend



**U.S. Business has maintained ~60% market share with four generics on the market**

**Most branded drugs lose ~90% market share in first 90 days post generic launch**

**Exceptional for any drug facing two years of generic competition**



## Amarin Delivered Cumulative \$1BN Since Generic Launched and Has The Ability to Manage Profitability via Multiple Levers




**AMARIN HAS THE ABILITY TO LEVERAGE ALL THREE TOOLS TO MAINTAIN U.S. PROFITABILITY**



## Significant Efforts Taken To Control Costs And Lower Cash Burn

2022 Quarterly Cash Burn



### Fourth Quarter

#### Cash Flow Positive

- Cash balance at 12/31 approximately \$310M
- Delivered actual savings of \$50M in the second half of 2022 and on track to achieve \$100M by mid-2023
- Significant progress renegotiating supply purchase agreements - process ongoing
- Future cash investments will be success-driven related to launching sales in new countries





# 03


## **New Board and Leadership are Agents of Change**

---

Refreshed and Fit-for-Purpose Board Driving Amarin's Transformation; Per Wold-Olsen Brings Key Expertise and Leadership Needed to Guide Amarin's Next Phase

## Proactive Board Refreshment Process is Comprehensive, Independent and Transparent...

### Timeline



### Selection Criteria

- Considered over **30 candidates** against **clear selection criteria**, including expertise in:

	✓ Europe and International healthcare – commercial execution
	✓ Global M&A, business development and pharma partnerships
	✓ Pricing and reimbursement
	✓ Cardiovascular and related product launch experience
	✓ Capital markets and healthcare investment
	✓ Corporate governance

**~70% Refreshed Board; Six New Independent Directors Appointed Since 2022**



## ...Bringing in Broad and Relevant Experience to Support Amarin's Transformation

								ESG	
			EU / Int'l commercial execution	Blockbuster drug, pricing and reimbursement	Cardiovascular and related product launch experience	M&A, BD and global pharma partnerships	Capital markets and healthcare investment	Governance experience	Years expertise
	<b>Per Wold-Olsen</b> <i>Chairman since May 2022</i>	    	✓	✓	✓	✓	✓	✓	<b>30+</b> PHARMA AND COMMERCIAL
	<b>Karim Mikhail</b> <i>President &amp; CEO since Aug 2021</i>		✓	✓	✓	✓			<b>26+</b> PHARMA AND COMMERCIAL
	<b>Adam Berger</b> <i>Board member since Oct 2022</i>	  		✓	✓	✓	✓	✓	<b>30+</b> OF FINANCIAL EXPERTISE
	<b>Erin Enright</b> <i>Board member since May 2022</i>	  				✓	✓	✓	<b>29+</b> FINANCIAL AND GOVERNANCE
	<b>Jan van Heek</b> <i>Board member since Feb 2010</i>	 	✓	✓			✓	✓	<b>30+</b> PHARMA COMMERCIAL AND MANUFACTURING
	<b>Geraldine Murphy</b> <i>Board member since Oct 2022</i>	 	✓			✓	✓	✓	<b>30+</b> PHARMA AND COMMERCIAL
	<b>Kristine Peterson</b> <i>Board member since Nov 2010</i>	  		✓	✓	✓		✓	<b>30+</b> PHARMA AND COMMERCIAL
	<b>Murray Stewart</b> <i>Board member since January 2023</i>	 	✓	✓	✓			✓	<b>27+</b> MEDICAL, CARDIO, GOVERNANCE
	<b>Alfonso "Chito" Zulueta</b> <i>Board member since May 2022</i>		✓	✓	✓	✓		✓	<b>30+</b> PHARMA, COMMERCIAL AND GOVERNANCE



## Per Wold-Olsen's Experience and Leadership are Having a Profound Impact on Amarin's Transformation



### Wealth of Highly Relevant Experience to Draw Upon

<p>✓ Possesses the leadership and expertise needed to guide Amarin's transformation:</p> <ul style="list-style-type: none"> <li>• Doubled Merck's European revenue</li> <li>• Maintained profitability during patent cliffs</li> <li>• Restructured CEE/MENA business, growing sales 6x</li> <li>• In charge of global franchise marketing for Merck's Human Health Division</li> </ul>	<p>✓ Unique and fresh value proposition identified by third party:</p> <ul style="list-style-type: none"> <li>• An independent search firm identified Per Wold-Olsen as a candidate in 2021</li> <li>• Per Wold-Olsen appointed to the Board in Jan 2022 and made Chairman in May 2022</li> <li>• Per Wold-Olsen is bringing the fresh perspectives Amarin needs</li> </ul>	<p>✓ Best-in-class Governance Experience at Leading Pharmaceutical Companies:</p> <ul style="list-style-type: none"> <li>• Board Member and/or leadership experience at <b>Great Nordic, H.Lundbeck, Novo Holdings, Gilead and Oncopeptides</b></li> <li>• Prior experience with healthcare policy committees providing connectivity with key industry players</li> </ul>
---	---	---

### Leadership and Achievements as Chairman to Date

<ul style="list-style-type: none"> <li>✓ Provided critical assistance to navigate EU pricing negotiations, leveraging prior experience with highly successful Zocor launch</li> <li>✓ Prior experience and relationship with EU payors</li> <li>✓ Recognized the need for cost containment</li> </ul>	<ul style="list-style-type: none"> <li>✓ Successfully achieved very favorable pricing outcomes in 5 countries</li> <li>✓ Critical to ongoing negotiations, with 5 approvals approaching finalization</li> <li>✓ Annual cost savings of \$50M achieved with \$100M targeted in 2023</li> </ul>
---	---



FEBRUARY 23

30

# Commitment to High Standards of Corporate Governance Drives Alignment and Accountability

**Robust and active board refreshment**

Ongoing refreshment to bring diverse perspectives, skills and experiences aligned with the long-term growth strategy

- ✓ 7 directors added in the past 2 years
- ✓ Median director tenure of less than 1 year
- ✓ 50%+ of the Board is diverse in gender/ethnicity

**Shareholder engagement**

Active shareholder engagement program, and the Board and are open to listening to the perspectives and constructive ideas from shareholders

- ✓ Dedicated investor relations team responsive to shareholders
- ✓ Shareholders can write to the corporate secretary to communicate with the Board and its individual members
- ✓ Shareholders have the right to call special meetings

**Governance features**


Best in class corporate governance features

- ✓ Majority vote standard for director elections
- ✓ Annual say-on-pay vote



## Compensation Structure Strongly Aligns Management and Shareholder Interests

Target CEO Compensation 2021



### Compensation Awarded Based on Robust and Measurable Performance Goals including:

- U.S. Commercial Profitability Improvement
- European Commercialization
- International Expansion
- R&D / Business Development
- Supply Goals
- Financial Goals

### PROVISIONS ALIGN WITH SHAREHOLDER INTEREST

- ✓ Pay levels are market aligned
- ✓ Predominantly at-risk compensation mix
- ✓ Rigorous performance metrics aligned with long-term value creation drivers
- ✓ Maximum payout caps on cash and performance RSUs payouts
- ✓ Stock ownership guidelines for executives and directors
- ✓ Double-trigger change in control provisions

**Amarin's Executive Compensation Program is Aligned with Our Long-Term Growth Strategy**



# 04


## **Sarissa's Campaign is Misguided and Risks Value Destruction**

---

Sarissa Does Not Understand Our Business and is NOT the Answer:  
It Has No Plan, No New Ideas and Its Director Slate is Underqualified



## Sarissa has Shown No Interest in Constructively Engaging or Offering New Ideas





## Sarissa's Director Slate is Underqualified Relative to the Existing Board, and Do Not Bring Additive Skills

### Board overview & relevant experience

■ Sarissa Employees

Board member	Patrice Bonfiglio	Paul Cohen <sup>1</sup>	Mark DiPaolo	Keith L. Horn	Odysseas Kostas	Louis Sterling III	Diane E. Sullivan <sup>1</sup>	Amarin's Existing Board
EU / Int'l commercial execution	X	X	X	X	X	X	?	✓ (6/9 members)
Blockbuster drug, pricing and reimbursement	X	X	X	X	X	X	?	✓ (7/9 members)
Cardiovascular and related product launch experience	X	?	X	X	X	X	✓	✓ (6/9 members)
M&A, BD and global pharma partnerships	X	X	X	✓	X	X	X	✓ (7/9 members)
Capital markets and healthcare investment	✓	?	✓	✓	✓	✓	X	✓ (5/9 members)
Governance experience	X	X	✓	✓	✓	✓	X	✓ (8/9 members)

**Sarissa's Directors Would Unnecessarily Crowd the Board  
and Waste Valuable Shareholder Resources**



FEBRUARY 23 <sup>1</sup> Amarin intends to interview Paul Cohen and Diane E. Sullivan to determine whether or not they have the experience necessary as part of the ongoing Board of Directors refreshment process

## Sarissa's Nominees Will NOT Advance Amarin's Transformation...

### Patrice Bonfiglio

Current Public Boards: None  
 Primary Industry Experience: Finance  
 Age: 40

*Patrice Bonfiglio's expertise is unsuited to Amarin's needs, with minimal operational experience outside of financial services*

- ✗ Experience in financial services is **not needed** by Amarin
- ✗ Has only served in finance and accounting roles for financial institutions – completely unrelated to Amarin's business
- ✗ Has **never** served on a public company board

### Paul Cohen

Current Public Boards: None  
 Primary Industry Experience: Cardiometabolic research  
 Age: 48

*Paul Cohen's expertise is primarily research-focused*

- ✗ Experience is primarily in academia
- ✗ Has not served on a public company board

*Amarin intends to interview Paul to determine whether he has relevant experience as part of the ongoing Board refreshment process*

### Mark DiPaolo

Current Public Boards: Innoviva  
 Primary Industry Experience: Finance / governance  
 Age: 52

*Mark DiPaolo's expertise is primarily investment related, and will not further Amarin's core commercialization focus*

- ✗ Primary experience in financial services and investing is **not additive** to Amarin's commercial efforts



FEBRUARY 23

36

## ...And Have a Lack of Governance and Commercial Experience

### Keith Horn

**Current Public Boards:** None

**Primary Industry Experience:** Finance and Real Estate

**Age:** 64

*Keith Horn's prior investments have been heavily real estate centric – an entirely different industry from Amarin*

- ✗ **Experience is primarily in financial services** with prior investments focused in real estate
- ✗ Virtually no experience in health care or international commercialization

### Odysseas Kostas

**Current Public Boards:** Innoviva, Armata Pharmaceuticals

**Primary Industry Experience:** Finance, Medicine

**Age:** 48

*Odysseas Kostas has no direct experience commercializing new therapies and is limited value-add*

- ✗ Experience is primarily in financial services and investments – **not additive to Amarin's existing Board skillset**

### Louis Sterling III

**Current Public Boards:** The Green Organic Dutchman

**Primary Industry Experience:** Finance, Law

**Age:** 44

*Louis Sterling has limited experience in ex-US commercialization; only prior Board seat with a marijuana company*

- ✗ Louis Sterling has limited experience in ex-US commercialization
- ✗ **Only prior Board seat unrelated to Amarin's focus**

### Diane Sullivan

**Current Public Boards:** None

**Primary Industry Experience:** Business development

**Age:** 60

*Diane Sullivan had limited impact at MedCo before it was sold, and her skillset is duplicative of members of our Board*

- ✗ Limited international experience

*Amarin intends to interview Diane to determine whether she has relevant experience as part of the ongoing Board refreshment process*



## Sarissa has Claimed Amarin Does Not Engage with Shareholders, However Amarin's New Management Has Made Engagement a Top Priority



**Communications and IR team fully refreshed during 2022**

**Redesigned Corporate Website**

Launched in Jan'23 with increased investor engagement functionality

**Key IR initiatives for 2H'22**

Quarterly town halls, direct Q&A with investors

**10+ Conferences Attended**


Since Karim's appointment as CEO

**AMARIN HAS BEEN BUILDING BETTER TOOLS TO ENGAGE WITH SHAREHOLDERS AND WILL USE THEM TO DRIVE ACTIVE DIALOGUE WITH ALL SHAREHOLDERS**



## **New Amarin: Right Plan, Right Team to Drive Shareholder Value**

- ✓ **Transformation to New Amarin is Underway**
- ✓ **Winning Commercial Strategy to Drive Short- And Long-Term Value Creation**
- ✓ **New Board Members are Agents of Change**
- ✓ **Sarissa's Campaign is Misguided and Risks Value Destruction**



**BOLD**

Leading a new paradigm  
in preventive cardiovascular  
care and growing our impact  
for patients globally

**AMBITIONS for**  **AMARIN®**

**Vascepa**<sup>®</sup>  
(icosapent ethyl)

**Vazkepa**<sup>®</sup>  
(icosapent ethyl)

# THANK YOU



FEBRUARY 23

 **AMARIN**<sup>®</sup>